Anthropic's IPO Filing Raises a $10 Billion Question: Who Can Say No?

Anthropic's October 26 IPO filing gives investors a question they usually postpone until a crisis: who inside an AI company can force it to miss a revenue target?

The scenario is concrete. A CEO faces a launch delay after customers have been promised delivery and computing capacity has been reserved. The safety team wants more testing. Sales wants the release. The CFO sees a hole opening in the quarter. Everyone endorsed responsible AI when it was a mission statement. Now someone has to sign off on a missed quarter — and the filing shows exactly who that someone is, and who can't hold them to it.

What power does the Long-Term Benefit Trust actually hold?

Anthropic's proposed charter gives its Long-Term Benefit Trust the right to elect a board majority, with additional approval requirements for one seat. That is substantial institutional power.

The filed trust agreement, however, sets a demanding threshold for outside shareholders who want to enforce its terms. An investor or group must hold at least 10% of the voting power of "Non-Trust Voting Shares" continuously for at least one year, and maintain that threshold throughout litigation. The calculation excludes trustee-owned shares and the founders' Class F share. Voting trustees, the company, and the Class F holder hold separate enforcement rights.

These restrictions govern enforcement of the trust, not every shareholder remedy. An investor who doesn't qualify depends on other authorized parties to enforce it. Institutional protection, in short, is not the same as individual recourse.

Who decides whether a model ships?

The filing describes a structured release process. Before each model release, Anthropic's Frontier Red Team analyzes capabilities that could assist cyberattackers. Development and deployment decisions are made case by case. Assessments may lead the company to delay releases, restrict access, or withhold a model from general use. A board safety and risk committee helps oversee model safety and security.

The company's separate Responsible Scaling Policy names the decision-makers. Under its Risk Report process, the CEO and the Responsible Scaling Officer make the ultimate determination on the adequacy of risk assessments and the resulting development or deployment plans. When proceeding relies heavily on the argument that Anthropic's systems add relatively less risk given the risks other AI systems unavoidably pose, both the board and the Long-Term Benefit Trust must explicitly approve the Risk Report.

These are substantive safeguards. But investors should still ask how disagreements among management, the board, and the trust would be resolved, who ensures required approvals are obtained before proceeding, and whether those arrangements can withstand the financial pressure of a delay.

What should boards across the industry test?

The practical test has three parts: authority to pause, money to sustain the delay, and consequences for bypassing the rules.

First, make pause and override authority explicit. Specify who can impose a pause, what evidence triggers it, what must change before restarting, and who can authorize an override. Any override should identify the decision-maker and record the reasons before release. The CEO should not be able to proceed first and explain later.

Second, fund the pause. Ask the CFO to model a 90-day delay before approving the launch. Which computing bills continue? What customer obligations remain? What happens to cash, guidance, and compensation? Ninety days is a stress test, not a universal standard. The point is discovering whether exercising the safeguard would trigger a financial crisis. A board that budgets for acceleration but leaves no capacity for restraint has already tilted the decision.

Third, decide what happens when management bypasses a safeguard. Require prompt escalation to the responsible board committee, a corrective-action plan, and clear consequences for unauthorized overrides.

What does this mean for buyers and investors?

Companies buying AI should negotiate notice when promised protections materially change, rights to remediation, and an exit where feasible. Investors should know who can enforce each promise and what they can demand if it is broken.

Before launch, the drill is simple: rehearse a failed safety review — who stops release, who funds the delay, and who authorizes a restart.

These arrangements won't guarantee safe AI. They will expose the point at which a company's promises exceed its willingness to pay for them. The competitive opportunity is larger than avoiding a bad headline: credible restraint can give enterprise customers a reason to trust a supplier with consequential work, supporting long-term relationships — but it costs money to maintain.

A promise can survive on paper. The ability to honor it may not survive the budget.